Cystic fibrosis transmembrane conductance regulator (CFTR), the channel mutated in cystic fibrosis (CF), is expressed by the biliary epithelium (i.e., cholangiocytes) of the liver. Progressive clinical liver disease (CF-associated liver disease; CFLD) occurs in around 10% of CF patients and represents the third leading cause of death. Impaired secretion and inflammation contribute to CFLD; however, the lack of human-derived experimental models has hampered the understanding of CFLD pathophysiology and the search for a cure. We have investigated the cellular mechanisms altered in human CF cholangiocytes using induced pluripotent stem cells (iPSCs) derived from healthy controls and a DF508 CFTR patient. We have devised a novel protocol for the differentiation of human iPSC into polarized monolayers of cholangiocytes. Our results show that iPSC-cholangiocytes reproduced the polarity and the secretory function of the biliary epithelium. Protein kinase A/cAMP-mediated fluid secretion was impaired in DF508 cholangiocytes and negligibly improved by VX-770 and VX-809, two small molecule drugs used to correct and potentiate DF508 CFTR. Moreover, DF508 cholangiocytes showed increased phosphorylation of Src kinase and Toll-like receptor 4 and proinflammatory changes, including increased nuclear factor kappa-light-chain-enhancer of activated B cells activation, secretion of proinflammatory chemokines (i.e., monocyte chemotactic protein 1 and interleukin-8), as well as alterations of the F-actin cytoskeleton. Treatment with Src inhibitor (4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyramidine) decreased the inflammatory changes and improved cytoskeletal defects. Inhibition of Src, along with administration of VX-770 and VX-809, successfully restored fluid secretion to normal levels. Conclusion: Our findings have strong translational potential and indicate that targeting Src kinase and decreasing inflammation may increase the efficacy of pharmacological therapies aimed at correcting the basic DF508 defect in CF liver patients. These studies also demonstrate the promise of applying iPSC technology in modeling human cholangiopathies. (HEPATOLOGY 2018; 67:972-988).
SEE EDITORIAL ON PAGE 833
C ystic fibrosis (CF) is an autosomal-recessive multisystemic disease caused by mutations in the gene coding for the CF transmembrane conductance regulator (CFTR), a cAMP-dependent Cl 2 channel expressed at the apical membrane of secretory epithelia, including the biliary epithelium. (1) (2) (3) Around 30% of CF patients present liver abnormalities (CF-associated liver disease; CFLD) and in around Abbreviations: 3D, three-dimensional; AE2, anion exchange protein 2; AFP, alpha fetoprotein; ASBT, sodium-dependent bile acid transporter; ASL, apical surface liquid; CF, cystic fibrosis; CFLD, CF-associated liver disease; CFTR, CF transmembrane conductance regulator; CFTR-KO, CFTR knockout; CK7, cytokeratin 7; CK19, cytokeratin 19; DAPI, 4 0 ,6-diamidino-2-phenylindole; FDA, U.S. Food and Drug Administration; FITC, fluorescein isothiocyanate; GGT, gamma-glutamyltransferase; HNF1b, hepatocyte nuclear factor 1 homeobox B; HNF4a, hepatocyte nuclear factor 4 alpha; IBMX, 3-isobutyl-1-methylxanthine; IL8, interleukin-8; iPSCs, induced pluripotent stem cells; KRB, Krebs-Ringer bicarbonate buffer; LPS, lipopolysaccharide; MCP-1, monocyte chemotactic protein 1; NF-jB, nuclear factor kappa-light-chain-enhancer of activated B cells; PBS, phosphate-buffered saline; PKA, protein kinase A; PPARc, peroxisome proliferator-activated receptor gamma; PP2, 4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo [3,4-d] pyramidine; RT, room temperature; SCRT, Secretin receptor; SOX9, SRY-box 9; Src, Rous sarcoma oncogene cellular homolog; TER, transepithelial resistance; TLR4, toll-like receptor 4; WT, wild type; ZO-1, zona occludens-1.
10% a chronic cholangiopathy progresses into sclerosing cholangitis and eventually focal biliary cirrhosis and liver transplantation. (4, 5) Improved care of lung disease has significantly increased the life expectancy in CF patients, and now CFLD represents the third cause of death in CF. (6) In the biliary epithelium, CFTR promotes the transmembrane efflux of chloride and bicarbonate and bile secretion in response to cAMP/PKA (protein kinase A) signaling. (7) The pathogenesis of CFLD is still unclear, and there is no specific genotype/phenotype correlation. In general, CFLD patients harbor severe mutations that are mostly associated with absent or decreased CFTR at the membrane and decreased secretion of HCO 3 2 . (8, 9) Around two thirds of CF patients carry a deletion of a phenylalanine in position 508 (DF508) that affects CFTR function by preventing its trafficking to the plasma membrane, as well as by causing a gating defect and decreased CFTR halflife when rescued. (10) DF508 patients have a higher risk of developing CFLD. (11) A cure for CFLD is not available and patients are routinely treated with ursodeoxycholic acid in the hope to increase bile flow, known to be reduced in CF, and to decrease bile acid toxicity. (12) Novel agents acting on the DF508 mutation and able to increase CFTR transport to the membrane (correctors) and to increase the activity of the rescued CFTR (potentiators) are being used to treat human lung disease, but there are no data regarding their use in CFLD. (13) The prospects for curative treatments are hampered by a lack of clear understanding of the pathogenesis of CFLD. The classic hypothesis that reduced CFTR causes ductal cholestasis and therefore biliary damage, has been challenged by recent studies in CFTR knockout (CFTR-KO) mice, showing that, in addition to its secretory functions, CFTR is critical to control the innate immune properties of biliary cells and the structural polarity of the epithelium. (14, 15) At the apical membrane of the cell, CFTR assembles a protein complex able to maintain Src tyrosine kinase in an inactive state. In CFTR-KO cells, this protein complex does not assemble, Src self-activates and phosphorylates Toll-like receptor 4 (TLR4). Phosphorylation enhances the activity of TLR4 in response to endogenous or exogenous ligands (i.e., lipopolysaccharide [LPS]). As a result, nuclear factor kappa-light-chain-enhancer of activated B cells (NF-jB) activity increases, instructing the epithelium to secrete a number of proinflammatory cytokines able to attract inflammatory cells and damage the bile ducts. Furthermore, the increased inflammatory status of CFTR-KO cholangiocytes affects the organization of F-actin cytoskeleton and the cell junctional complexes impairing the barrier function of the epithelium.
Inhibition of Src or NF-jB and the use of peroxisome proliferator-activated receptor gamma (PPARc) agonists in vivo ameliorates liver damage in CFTR-KO mice, indicating that this is indeed a disease-relevant mechanism. (15) Whether this mechanism is relevant for the human disease it is unknown. Therefore, studies in a human cellular model are necessary to validate the findings and to exploit their therapeutic implications.
In this study, we took advantage of iPSC technology to generate a well-differentiated human cholangiocyte model bearing the DF508 defect suitable to study the pathophysiological mechanisms responsible for cholangiocyte dysfunction that might be therapeutically targeted and translated into clinical applications. We have used this model to address the role of CFTR in innate immunity and fluid secretion and to study how novel therapeutic molecules affect epithelial functions in CF. The results strongly advocate for the value of multitarget combination treatments in CF.
Materials and Methods
Reagents and additional methods are detailed in the Supporting Materials and Methods.
HUMAN iPSC GENERATION AND CULTURE
Control iPSCs were obtained from the Coriell cell repository and from Dr. Flora Vaccarino, Yale University (New Haven, CT). These lines were generated using the classical retroviral approach through the ectopic expression of the canonical transcription factors, octamer-binding transcription factor 4, Kruppellike factor 4, SRY-box, and cMyc. (16, 17) DF508-iPSCs were a gift of Dr. Laura E. Niklason, Yale University, and were generated in the laboratory of Dr. Darrel Kotton, Boston University (Boston, MA), by a viral free reprogramming method using a single excisable polycistronic lentiviral Stem Cell Cassette (STEMCCA) encoding the Yamanaka factors. (18) All human iPSC lines were maintained in defined culture conditions on Matrigel (Corning Inc., Corning, NY) coated plates in mTEsR media (STEMCELL Technologies Inc., Vancouver, British Columbia, Canada).
DIFFERENTIATION OF CHOLANGIOCYTES FROM iPSCs AND EXPANSION
A detailed description of the protocol is reported in the Supporting Materials and Methods section.
POLARIZATION OF iPSC-CHOLANGIOCYTES AND MEASUREMENT OF TRANSEPITHELIAL RESISTANCE
To obtain a polarized monolayer, either hepatoblasts or iPSC-cholangiocytes in expansion were seeded on top of collagen-coated transwell inserts with a 0.4-lm pore semipermeable membrane (Corning Inc.), and the same media was applied apical and basolateral. In this condition, cells grow as a polarized monolayer accessible from both the apical and basolateral domain distinctly. Establishment of a confluent monolayer was routinely checked, measuring transepithelial resistance (TER; Millicell ERS System; EMD Millipore, Billerica, MA). Cells were confluent and ready for further experiments when TER was >1,000 XÁcm 2 . Where indicated, cells were treated with VX-770 and VX-809 (10 uM; Selleck Chemicals LLC, Houston, TX) for 24 hours and 4-amino-5-(4-chlorophenyl)-7-(tbutyl)pyrazolo [3,4-d] pyramidine (PP2; 1 uM; EMD Millipore) for 2 hours.
ANIMALS
All procedures involving animals in this study were approved by the Yale University Institutional Animal Care and Use Committee according to the criteria outlined in the Guide for the Care and Use of Laboratory Animals prepared by the National Academy of Sciences and published by the National Institutes of Health (NIH publication 86-23 revised 1985). DF508-CFTR (B6-129-Cftr tm1Kth ) (19) mice with targeted mutation corresponding to the DF508 mutation in humans were used for the isolation of primary cholangiocytes cell lines. Animals were bred in our facility and were maintained as described. (14, 20, 21) 
IMMUNOFLUORESCENCE AND CONFOCAL MICROSCOPY
Mouse and human cholangiocytes were fixed with either (1) 1:1 methanol/acetone solution and washed with phosphate-buffered saline (PBS); (2) or with 4% paraformaldehyde, washed with PBS/10 mM of glycine, and permeabilized with PBS/TritonX-100 0.2%. Unspecific binding sites were blocked with Protein Block Serum-Free solution (Dako, Agilent Technologies, Santa Clara, CA) for 1 hour at room temperature (RT). Cells were then incubated overnight at 48C with specific primary antibody (see Supporting Table S1 ) and with the proper secondary antibody for 1 hour at RT. Cells were then mounted using a Vectashield Kit (Vector Laboratories, Burlingame, CA) with 4 0 ,6-diamidino-2-phenylindole (DAPI). Confocal analysis was performed using a Zeiss LSM 710 Duo confocal microscope or a Zeiss LSM510 Meta (Zeiss, Thornwood, NY).
DETERMINATION OF CYTOKINE SECRETION
Polarized iPSC-derived cholangiocytes were untreated or treated with PP2 (1 lM), LPS (10 ng/mL; Sigma-Aldrich, St Louis, MO) or their combination for 24 hours. At the end of the treatment, apical media were collected and processed for monocyte chemotactic protein 1 (MCP-1) and interleukin-8 (IL8) quantification analysis by using the Milliplex MAP Human Cytokine/Chemokine Magnetic Bead Panel (EMD Millipore) coupled with BioPlex Luminex platform (Bio-Rad Laboratories, Hercules, CA), following the manufacturer's instructions. Data were normalized for the cell protein content as described. (14) MEASUREMENT OF APICAL SURFACE LIQUID Fluid level at the apical membrane of confluent human and mouse cholangiocyte monolayers was quantified according to a modified technique. (22) Briefly, confluent monolayers of cholangiocytes were washed with PBS and labeled with CellMask Orange Plasma membrane Stain (1:1,000; Invitrogen, Life Technologies, Carlsbad, CA) for 10-15 minutes at 378C. To label the apical surface liquid (ASL), 20 uL of Krebs-Ringer bicarbonate buffer (KRB) containing 0.5 mg/mL of fluorescein isothiocyanate (FITC)-dextran (40 kDa) was added to the apical surface of the monolayer and 100 uL of Fluorinert FC-770 (SigmaAldrich) was layered on the top to prevent evaporation. Transwells were then placed on the surface of a glassbottomed MatTek 35-mm dish (MatTek Corp, Ashland, MA) over a serosal reservoir of 80 uL (KRB) and left in the incubator for 30 minutes. A mix of forskolin (10 uM) and 3-isobutyl-1-methylxanthine (IBMX; 100 uM; Sigma-Aldrich) were dissolved in the serosal reservoir and in the dextrans mixture, where indicated. Transwells were then mounted in an incubator that maintains 378C and 5% CO 2 on the stage of a Zeiss LSM 710 Duo confocal microscope and images acquired with the Zeiss AIM software. Samples were imaged using a 403 water immersion lens. XZ highresolution images (512 3 96 pixels) were acquired from different points of each transwell using the same electronic gain, offset, and laser powers. The surface area covered by dextrans (square pixels) was measured by ImageJ software (NIH, Bethesda, MD) by applying a fluorescence threshold to obtain the average ASL in different conditions.
STATISTICAL ANALYSIS
Data are shown as means 6 SD and compared using the Student t test or analysis of variance with repeated measures, when appropriate. All tests were two-sided. Statistical analyses were carried out using GraphPad Prism. A P value of less than 0.05 was considered statistically significant.
Results

SUCCESSFUL DIFFERENTIATION OF HUMAN iPSCs INTO MATURE, POLARIZED CHOLANGIOCYTES OPTIMIZED FOR PATHOPHYSIOLOGICAL AND PHARMACOLOGICAL APPLICATIONS
Recent studies have shown that it is possible to differentiate human iPSC cells into cholangiocyte-like cells. (23) (24) (25) (26) To use this technology as a bona-fide disease model and a platform to conduct cell biology studies we have spent significant effort in optimizing several methodological aspects, to generate a competent epithelium, improve its functional polarity and produce sufficient amounts of cells to study (see Materials and Methods).
Human iPSC lines were differentiated into biliary epithelial cells (cholangiocytes) by modifying the protocol published by Dianat et al. (24) (see Materials and Methods). Briefly, iPSCs were sequentially exposed to signals involved in liver development and "accompanied" through the following sequential steps: definitive endoderm, hepatic endoderm, and hepatoblasts, that is, the common progenitors of hepatocytes and cholangiocytes. A schematic representation of the protocol is shown in Fig. 1A . Using this protocol, we were able to reproducibly differentiate iPSCs into cholangiocytes with high efficiency. By immunohistochemistry (Fig. 1B) , iPSCderived cholangiocytes expressed specific biliary markers, such as cytokeratin 19 (CK19), cytokeratin 7 (CK7), hepatocyte nuclear factor 1 homeobox B (HNF1b), Characterization by immunoflurescence shows the expression of biliary specification markers and enzymatic activity for GGT at the end of the differentiation process (day 21). (C) Gene expression profile shows that iPSC-derived cholangiocytes (day 21) express high levels of biliary specification markers compared to hepatoblasts (day 12) whereas the hepatocyte marker, HNF4a, and the progenitor marker, AFP, are significantly decreased. Bars represent means 6 SD of n 5 3 independent differentiation experiments. *P < 0.05; **P < 0.01 Abbreviations: DE, definitive endoderm; DMSO, dimethyl sulfoxide; HE, hepatic endoderm; HB, hepatoblasts; Chol, cholangiocytes; SR, KO-serum replacement; EGF,epidermal growth factor; HGF, hepatocyte growth factor; RA, retinoic acid; FGF, fibroblast growth factor; IL6, interleukin-6. SRY-box 9 (SOX9), and the NOTCH2 intracellular domain, and were also positive for the sodiumdependent bile acid transporter (ASBT) and gammaglutamyltransferase (GGT). Gene expression of functional cholangiocyte markers, such as CFTR and the membrane-bound bile acid receptor, TGR5, was also present, whereas markers typical of hepatoblast, such as hepatocyte nuclear factor 4 alpha (HNF4a) and alpha fetoprotein (AFP) were down-regulated (Fig. 1C) .
The apicobasal polarity is a key feature of a mature biliary epithelium that deeply influences its function; therefore, we optimized culture conditions to enable the establishment of polarized monolayers. To achieve this goal, iPSCs at the stage of hepatoblast differentiation were plated on top of collagen-coated transwell inserts before inducing cholangiocytes specification. Cholangiocyte monolayers obtained under these conditions acquired the characteristics of a tight epithelium with a competent TER >1,000 XÁcm 2 (Supporting Fig. S1 ). The localization of the tight junction marker, zona occludens-1 (ZO-1), at the apical cell junction, the presence of primary cilia on the apical membrane ( Fig. 2A) and the basolateral localization of functional secretin receptors ( Fig. 2B ; see below) confirmed the differentiation of iPSC-derived liver cells into mature cholangiocytes (iPSC-cholangiocytes) that acquire apicobasal polarity when cultured as a monolayer.
cAMP signaling, in response to the hormone secretin that binds its receptor at the basolateral membrane, represents the main pathway regulating Cl 2 and HCO 3 2 secretion in biliary cells. (27, 28) To assess the functional maturation of polarized iPSC-cholangiocytes, we evaluated their intracellular cAMP production in response to secretin exposure; forskolin (10 uM) was used as a positive control (Fig. 2B) . Consistent with basolateral expression of functional secretin receptor, stimulation of cholangiocytes with secretin (50 nM and 100 nM) led to a dose-dependent significant increase in intracellular cAMP levels when administered from the basolateral, but not from the apical, side.
The use of iPSC-cholangiocytes for cell biology studies requires the availability of a large number of cells. Starting a new differentiation from iPSCs for every experiment would be time-consuming, expensive, and subject to significant variability. To solve these issues, we devised a method that allowed us to subculture and expand iPSC-cholangiocytes for up to 10 passages (see Materials and Methods).
At the end of the differentiation period, cholangiocytes were harvested and plated on collagen-coated flasks and supplemented with an enriched media (see Materials and Methods for details). As shown by immunofluorescence and real-time qPCR, these cells maintained specific biliary markers expression at the same or higher level compared to the iPSCs at the end of the differentiation (Fig. 3A,B) .
Having optimized the protocol and culture conditions in healthy controls, we then differentiated iPSCcholangiocytes obtained from a patient carrying the most common CFTR mutation, DF508, in homozygosis (Supporting Fig. S2 ). As expected, both control and mutated cholangiocytes expressed CFTR at the mRNA level, but in the case of DF508 cholangiocytes, the glycosylated mature form of the protein was not detected by western blotting (Fig. 4A ). Functional and morphological characterization of DF508 cholangiocytes was similar to the one above described for normal cholangiocytes, as also shown by similar gene and protein levels of expression of secretin receptor (SCRT) and anion exchange protein 2 (AE2; Fig. 4A ).
cAMP-STIMULATED SECRETION IS DEFECTIVE IN HUMAN CHOLANGIOCYTES DERIVED FROM DF508-iPSCs
We quantified the cAMP-stimulated secretory function in normal and mutated cells by ASL measurement (see the Materials and Methods section for further details). To define the apical surface of the epithelium, human cholangiocytes cultured as polarized monolayers were visualized with the membrane dye, CellMask, whereas fluorescent dextrans (40 kDa) were applied on top of the monolayers. Following stimulation with forskolin (10 uM) in the presence of the phosphatase inhibitor, IBMX (100 uM), for 30 minutes, cells were live-imaged by confocal microscopy and serial z-stack images were acquired. The threshold area of the fluorescent dextrans on top of the epithelium was used as a parameter to quantify fluid secretion (Fig. 4B) . Treatment with forskolin significantly increased apical secretion of fluid in control iPSC-cholangiocytes, but not in cholangiocytes from the DF508 iPSC, consistent with the expected secretory defect (Fig. 4C) .
PROINFLAMMATORY CHANGES IN DF508-MUTATED HUMAN CHOLANGIOCYTES
Using a full knockout rodent model for CFTR (CFTR tm1UNC , CFTR-KO), we have recently showed that CF cholangiocytes respond to LPS with increased activation of the TLR4/NF-jB pathway and excess production of proinflammatory cytokines as a result of Src tyrosine kinase activation. (14, 15) However, it is, at present, unclear whether these findings can be translated to humans and to patients with the DF508 mutation.
Here, we show that, in human DF508 cholangiocytes, these changes are already quite evident at baseline, before challenging cells with LPS. In fact, NF-jB activity, measured using a reporter gene assay, (14) was significantly higher in DF508 cholangiocytes, with respect to control cells (Fig. 5A ). In addition, secretion . At the end of the treatment, cells were lysed and intracellular cAMP levels were quantified by enzyme-linked immunosorbent assay. A significant dose-dependent increase in cAMP after treatment with secretin only from the basolateral side is consistent with a functional receptor at the basolateral membrane. Forskolin, a broad activator of adenylyl cyclases, was used as a positive control. Bars represent means 6 SD of n 5 3-4 independent differentiation experiments. *P < 0.05; **P < 0.01 versus CTRL. Scale bar 5 10 lm. Abbreviations: AP, apical; CTRL, control; Secr, secretin. of MCP-1 and IL8, chemoattractants for proinflammatory monocytes and neutrophils, were also significantly increased at baseline with respect to control cholangiocytes (Fig. 5B) . Having shown increased NF-jB activity and cytokine secretion in human DF508 cholangiocytes, we focused on the events upstream. Western blotting analysis showed that TLR4 phosphorylation at the tyrosine 674 is significantly increased in DF508 cholangiocytes, as compared to normal cholangiocytes (Fig. 5C ). Furthermore, Src activity, measured as phosphorylation at the tyrosine 419 residue of the catalytic domain, is also increased in human cholangiocytes bearing the DF508 mutation, with respect to cholangiocytes normally expressing CFTR at the plasma membrane (Fig.  5D ). Next, we exposed control and DF508 cholangiocytes to LPS (10 ng/mL) and we measured NF-jB activation 6 hours later and MCP-1 and IL8 secretion 24 hours later. LPS treatment further increased significantly NF-jB activation and cytokines secretion in DF508 cholangiocytes (Fig. 5A,B) . To determine whether Src activation was upstream to the proinflammatory changes identified in DF508 human cholangiocytes, we repeated the experiments in the presence of the Src inhibitor, PP2 (1 lM). The significant decrease in NF-jB activation and in cytokine secretion after treatment with PP2 confirmed the pathophysiological role of Src in the inflammatory phenotype displayed by DF508 human cholangiocytes (Fig. 5A,B) .
THE DISTRIBUTION OF ACTIN CYTOSKELETON IS ALTERED IN DF508 CHOLANGIOCYTES
Changes in cytoskeleton have been reported in a number of cells and tissues in CF. (15, 29, 30) Working with CFTR-KO mice that completely lack CFTR, we suggested that the destabilization of F-actin fibers was a consequence of the increased activity of the Src kinase/TLR4/NF-jB pathway. (15) To study the integrity of the F-actin cytoskeleton in human DF508 cholangiocytes and controls, we analyzed phalloidin staining in polarized monolayers after fixation. Immunofluorescence revealed significant differences in Factin distribution between control and DF508 cholangiocytes. In control cells, F-actin was distributed at the area of apical membrane and cell-cell junctions, where normally the subcortical actin ring colocalizes closely with cell-cell junctions. On the contrary, in DF508 cells, a large amount of F-actin was delocalized and diffused in the cytoplasm significantly distorting the polygonal shape of the cells in the monolayer (Fig.  6A) . Interestingly, short-time treatment with the Src inhibitor, PP2 (1 uM), was able to recover the altered distribution of F-actin in human DF508 cells, indicating that changes in actin are a consequence of activation of Src kinase/TLR4/NF-jB pathway (Fig. 6B) .
The same defect was present also in primary cholangiocytes isolated from DF508-CFTR mice (B6-129-Cftr tm1Kth ) that bear a targeted mutation corresponding to the DF508 mutation in humans (Supporting Fig. S3 ).
Src INHIBITION INCREASES THE EFFICACY OF VX-770 AND VX-809 IN RESCUING THE DF508 DEFECT IN CHOLANGIOCYTES
The DF508 mutation causes multiple structural defects in CFTR. As a consequence, not only the majority of the protein is unable to reach the membrane, but also the stability of the DF508-CFTR that it is able to arrive at the cell surface is decreased. (31) FIG. 5. Src-kinase dependent proinflammatory changes are present in human DF508-chol. (A) NF-jB activity was measured by luciferin/luciferase reporter gene assay in human iPSC cholangiocytes in control conditions and after stimulation with LPS (10 ng/ mL) for 6 hours. Basal NF-jB activity was significantly elevated in DF508-chol as compared to controls and further increased after stimulation with LPS. NF-jB activity in DF508-chol was significantly decreased by treatment with an Src kinase inhibitor (PP2, 1 lM). Bar graph represents mean 6 SD of the relative luciferase activity in n 5 3 different experiments repeated in triplicate; *P < 0.05; **P < 0.01. (B) MCP-1 and IL8 concentration was determined by Luminex analysis in the apical medium of polarized human iPSC cholangiocytes. Values were normalized for total protein content. Both MCP-1 and IL8 were highly secreted by DF508-chol compared to controls. Secretion was significantly increased by treatment with LPS for 24 hours. Treatment with PP2 (1 lM) significantly decreased their concentration in DF508-chol. Bar graphs represent mean 6 SD of n 5 3 different experiments repeated in triplicate; **P < 0.01 versus Ctrl-chol; Ctrl, ## P < 0.01 versus DF508-chol Ctrl; ᭜ P < 0.05 versus Ctrl-chol LPS; ÙÙ P < 0.01 versus DF508-chol LPS. (C) TLR4 tyrosine (Y674) phosphorylation was determined by western blotting. Bar graph represents the ratio between p-TLR4 (pY674) and total TLR4. Tyrosine phosphorylation of TLR4 is significantly increased in DF508-chol. *P < 0.05. (D) Src activity was determined by western blotting using an antibody for Src (pY418). Bar graph represents the optical density ratio of p-Src (pY418)/total Src. DF508-chol show an increased amount of p-Src compared to Control-chol. *P < 0.05. Abbreviations: chol, cholangiocytes; Ctrl, control; p, phosphorylated.
FIOROTTO, AMENDUNI, ET AL. HEPATOLOGY, March 2018
The search for a pharmacological therapy able to correct the DF508 mutation has produced two small molecules (VX-770 and VX-809) recently approved by the U.S. Food and Drug Administration (FDA). (32, 33) VX-770 is a "potentiator" of the channel activity, whereas VX-809 works as a "corrector" allowing the DF508 CFTR to bypass proteomic degradation and increasing the trafficking of the protein to the plasma membrane. Unfortunately, in vitro studies (34) and recent clinical data (35, 36) show that the efficacy of these drugs may be decreased in long-term treatments, because the half-life of the rescued CFTR at the plasma membrane is lower than that of wild-type (WT) CFTR.
Thus, we tested the ability of VX-770 and VX-809 to recover the secretory function in iPSC-cholangiocytes bearing the DF508 mutation by measuring apical fluid secretion in polarized monolayers as described above. There was a moderate increase in forskolin-stimulated fluid secretion after treatment with the correctors in DF508 human cholangiocytes; however, secretion remained 80% less than that of normal human cholangiocytes (Fig. 7B,C) . We also found a similar low response in DF508 mouse cholangiocytes (Supporting Fig. S3) .
By western blotting analysis, we confirmed that the mature CFTR form was expressed in DF508 human cholangiocytes after treatment with VX-770 and VX-890 (see Fig. 7A ), suggesting that the small effect of treatment on fluid secretion is likely related to a predicted instability of DF508 CFTR at the membrane. The integrity and organization of the F-actin cytoskeleton is known to be necessary for CFTR retention at the plasma membrane and its association in multiprotein membrane complexes.
(37) Therefore, we reasoned that the normalization of F-actin distribution could have a "stabilizing" effect on the retention of the rescued DF508 CFTR at the membrane and would possibly improve the efficacy of the VX-770 and VX-809.
To this aim, we tested the effect of Src inhibition in combination with VX-770 and VX-890 in DF508 cholangiocytes on actin microfilaments distribution and fluid secretion. We treated polarized cholangiocytes with VX770 and VX-809 (10 uM) for 24 hours with or without PP2 (1 uM) that was administered 2 hours before analysis. As shown by phalloidin staining in Fig. 6A , F-actin organization partially improved after treatment with VX-770 and VX-809 (probably as an effect of more CFTR reaching the apical membrane), but did not fully normalize, unless the Src inhibitor, PP2, was administered in combination with VX-770 and VX-809. We demonstrated the same effect also in cholangiocytes isolated from mice carrying the mutation DF508 (Supporting Fig. S3 ). As we predicted, in cells treated with the combination of correctors and PP2, secretion was significantly improved, reaching levels comparable to normal cells (Figs. 4C  and 7B,C) . Fluid secretion did not improve after treatment with PP2 alone (Fig. 7C) , suggesting that PP2 does not affect the residual activity of DF508 CFTR that escaping the ER checkpoint eventually arrives at the membrane. The treatment with the combination of correctors and PP2 in DF508 cholangiocytes significantly increases the amount of the glycosylated mature form of DF508-CFTR. In addition, PP2 alone has a synergistic effect on foskolin-stimulated fluid secretion in control cells (Supporting Fig. S4 ). Altogether, these data suggest that normalizing F-actin by inhibition of Src kinase improves and potentiates the efficiency of the small molecules, most likely by increasing the stability of the rescued DF508 at the membrane or by decreasing the recycling of CFTR from the membrane.
Discussion
The recently discovered iPSCs technology provides a source of cells derived from patients that can be differentiated in the somatic cell of interest. iPSCderived cells retain the genetic background of the donor, making them a suitable tool for disease modeling. (38, 39) Recent studies have shown that it is possible to differentiate patient-derived iPSCs into liver epithelial cells and that these cells reproduce phenotypic features of the genetic disease of origin. (25, 26, 40) This is of great importance in CFLD, because the lack of a valuable human model has hampered research in the field. We have generated a modified protocol for the differentiation of iPSCs into cholangiocytes able to overcome some of the barriers to the routine use of this technology for cell biology studies and applied this system to model CFLD in vitro.
The pathogenesis of CFLD is unclear, and although it has been associated with the lack of CFTR function and of biliary bicarbonate secretion leading to ductal cholestasis, several open questions remain. (41) Our recent studies using a CFTR-KO mouse model have shown that altered TLR/NF-jB-dependent innate immune mechanisms and abnormalities of the cytoskeletal biliary cell structure could contribute to the pathogenesis of CFLD, and suggest that an attempt to restore only the secretory functions of the biliary epithelium may not be curative in itself. (14, 15) However, CF rodent models do not fully reproduce the human disease, thus we decided to use cholangiocytes generated from iPSCs derived from a CF patient to model the cystic fibrosis, to study whether our previous findings in rodents apply also to humans and to expand their translational implications.
To this aim, we devised an improved step-wise protocol that recapitulates the different stages of biliary development and allows us to culture and expand the iPSC-derived cholangiocytes. Our protocol presents two important improvements, compared with previously published studies. Notably, we were able to generate a polarized and functionally competent monolayer of cholangiocytes, as confirmed by the specific expression of markers, receptor-mediated response to secretin, and acquisition of a TER and polarized secretion. Culture in two-dimensional polarized conditions has the advantage to preserve the functional polarity of the epithelium while overcoming the difficult experimental accessibility of the apical domain in three-dimensional (3D) organoid cultures. In addition, we were able to subculture and expand our differentiated cholangiocytes, thus reducing the experimental cost and the variability of multiple differentiations.
We have used our protocol to model in vitro human CFLD and to validate in human cholangiocytes bearing the most prevalent pathogenetic mutation (DF508) the changes in innate immunity described in a CFTR-KO mouse model. There is still no correlation between the liver complications and specific CFTR mutations, but it is recognized that liver disease progresses in patients with more-severe mutations mainly associated with a loss of CFTR at the membrane. (8) Thus, we used iPSCs derived from a CF patient homozygous for the CFTR class II mutation, DF508, the most common mutation in CF. This mutation is caused by the deletion of three nucleotides in position 508 of the CFTR gene on chromosome 7, and produces an abnormal CFTR protein that is not properly folded and is unable to leave the endoplasmic reticulum for further processing. Therefore, the DF508 mutation prevents CFTR from reaching the apical membrane. A small percentage of the protein is still able to escape the ER checkpoint, but is not functional because of a gating defect and decreased half-life at the membrane. (10) We first confirmed that the mature form of CFTR was undetectable in human iPSC-derived DF508 cholangiocytes and that fluid secretion in response to increased intracellular cAMP was absent. Then, we tested the response to currently used therapeutic compounds. The FDA has recently approved a treatment to correct the DF508 defect in CF patients, based on the combination of a "potentiator" of the CFTR gating function (VX-770) and a "corrector" that allows CFTR to bypass proteomic degradation, thereby increasing its trafficking to the plasma membrane (VX-809). (33) Because no clinical data are available for CF liver patients with DF508, we tested their ability to correct the DF508 defect and rescue the impaired fluid secretion in iPSC-derived DF508-cholangiocytes. Although the treatment with combined VX-770 and VX-809 increased significantly the expression of the mature CFTR protein, as expected based on their pharmacological properties, their effect on cAMPstimulated CFTR-dependent fluid secretion was small and fluid secretion improved only by 20%, as compared to values in control cells.
However, total amount of cellular CFTR protein does not predict the actual level of protein present at the membrane. Indeed, our results on fluid secretion in human DF508 cholangiocytes are consistent with recent clinical reports on lung function from DF508 patients treated with the small molecules. Despite the encouraging results during phase III of the study, the actual efficacy of the new molecules in the clinic was not impressive because of the instability and reduced half-life of the rescued CFTR at the plasma membrane. The reason for the low efficacy has been attributed to the inflammatory status of the patients or to a negative interference of the drugs combination in long-term treatments. (34, 42) Interestingly, we found that human DF508 cholangiocytes are characterized by an increased basal NF-jB activation and actively secrete proinflammatory chemokines known to attract neutrophils (i.e., MCP-1 and IL8). Similar to our previous findings in CFTR-KO mice, human DF508 cholangiocytes show increased responsiveness to endotoxins compared to cholangiocytes control, as well as an increased Src tyrosine kinase activation and TLR4 phosphorylation. These data imply that in CF liver disease, there is a cell autonomous "autoinflammatory" component as a result of an aberrant activation of the innate immune system. We have also shown that direct inhibition of Src or NF-jB (through PPARc agonists) improves liver damage in a rodent model of CFLD. (15, 43) In addition to increased secretion of proinflammatory cytokines, we have observed the presence of structural alterations of the subcortical F-actin distribution in iPSC-derived cholangiocytes bearing the DF508 mutation as well as in DF508 mouse cholangiocytes. In polarized epithelia, actin filaments at the apical domain form an organized circumferential belt that connects the cell junctions. Actin distribution improved after Src inhibition in human DF508 cholangiocytes, suggesting that the defect is secondary to Src activation as a consequence of the inflammation. Indeed, several studies have documented that inflammatory mediators can induce a disassembly of the F-actin belt and cause the relocation of junction proteins into the cytosol, therefore affecting the epithelial barrier function. Intriguingly, a similar phenotype has been reported also in a human airway immortalized CF cell line expressing DF508-CFTR. (29) In physiological conditions, the integrity of the actin cytoskeleton is critical for CFTR tethering at the plasma membrane. (44, 45) Thus, we hypothesized that the altered distribution of subcortical cytoskeleton caused by the inflammatory responses of the biliary epithelium might decrease the stability of the rescued CFTR at the membrane and limit the efficacy of VX-770 and VX-809.
Because inhibition of Src tyrosine kinase reduces NF-kB activation and cytokine secretion and rescues F-actin distribution, if our hypothesis is correct, targeting Src should improve the efficacy of VX-770 and VX-809. Indeed, our study shows that treatment with a combination of CFTR potentiators/correctors and the Src inhibitor results in the restoration of the Factin architecture and in a parallel drastic increase in fluid secretion in DF508 cholangiocytes, both of human and mouse origin. Interestingly, Src inhibition also enhanced PKA-stimulated fluid secretion in control cells. Further studies will clarify whether Src kinase plays a role in the mechanism of recycling of the channel at the membrane In summary, we have developed an improved protocol for the generation of iPSC-derived human cholangiocytes in polarized monolayers. Our culture conditions allow cholangiocytes to reach a high level of functional maturation while expanding their experimental applicability for modeling of biliary diseases and drug screening compared with 3D cultures. We have derived human cholangiocytes from a CF patient with the common homozygous mutation, DF508 CFTR, and used them to model the liver disease. Using iPSC-derived cholangiocytes, we have unveiled the pathophysiological mechanism that underlies cholangiocyte dysfunction in CF and showed that CFTRdefective biliary cells present inflammatory and cytoskeletal changes affecting the ability to respond to current treatments. Normalization of these changes by Src inhibition strongly improves the efficiency of the small molecules active with the DF508 mutation. Our study has further proved that given the multiple functions of CFTR, its pharmacological therapy requires a combination of therapeutic approaches. Most likely these findings can be applied to other organs affected by CF, such as the airway epithelium and the pancreas.
